These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 21126843)

  • 21. Paclitaxel-coated balloon for the treatment of drug-eluting stent restenosis: subanalysis results from the Valentines I trial.
    Loh JP; Stella PR; Sangiorgi G; Silber S; Stahnke S; von Strandmann RP; Torguson R; Waksman R
    Cardiovasc Revasc Med; 2014 Jan; 15(1):23-8. PubMed ID: 24444473
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sirolimus- or paclitaxel-eluting stents to prevent coronary artery restenosis.
    Doggrell SA
    Expert Opin Pharmacother; 2004 Nov; 5(11):2209-20. PubMed ID: 15500367
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry).
    Fröbert O; Lagerqvist B; Carlsson J; Lindbäck J; Stenestrand U; James SK
    J Am Coll Cardiol; 2009 May; 53(18):1660-7. PubMed ID: 19406341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prospective multicenter parallel-controlled trial of TIVOLI biodegradable-polymer-based sirolimus-eluting stent compared to ENDEAVOR zotarolimus-eluting stent for the treatment of coronary artery disease: 8-month angiographic and 2-year clinical follow-up results.
    Xu B; Dou KF; Han YL; Lü SZ; Yang YJ; Huo Y; Wang LF; Chen YD; Wang HC; Li WM; Chen JY; Wang L; Wang Y; Ge JB; Li W; Gao RL
    Chin Med J (Engl); 2011 Mar; 124(6):811-6. PubMed ID: 21518585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Augmented re-endothelialization and anti-inflammation of coronary drug-eluting stent by abluminal coating with magnesium hydroxide.
    Jeong DW; Park W; Bedair TM; Kang EY; Kim IH; Park DS; Sim DS; Hong YJ; Koh WG; Jeong MH; Han DK
    Biomater Sci; 2019 May; 7(6):2499-2510. PubMed ID: 30957801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug-eluting stents: clinical experiences and perspectives.
    Grube E; Gerckens U; Buellesfeld L
    Minerva Cardioangiol; 2002 Oct; 50(5):469-73. PubMed ID: 12384629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug eluting stents: initial experiences.
    Grube E; Gerckens U; Müller R; Büllesfeld L
    Z Kardiol; 2002; 91 Suppl 3():44-8. PubMed ID: 12641014
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased restenosis rates 12 months after coronary implantation of the sirolimus-eluting YUKON-choice stent compared to the paclitaxel-eluting TAXUS Stent.
    Ruef J; Störger H; Schwarz F; Haase J
    Clin Cardiol; 2010 Apr; 33(4):E33-8. PubMed ID: 20358534
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integrity of stent polymer layer after drug-eluting stent implantation: in vivo comparison of sirolimus-, paclitaxel-, zotarolimus- and everolimus-eluting stents.
    Watanabe T; Fujita M; Awata M; Iida O; Okamoto S; Ishihara T; Uematsu M
    Cardiovasc Interv Ther; 2014 Jan; 29(1):4-10. PubMed ID: 23818255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fabrication and characteristics of dual functionalized vascular stent by spatio-temporal coating.
    Kim SM; Park KS; Lih E; Hong YJ; Kang JH; Kim IH; Jeong MH; Joung YK; Han DK
    Acta Biomater; 2016 Jul; 38():143-52. PubMed ID: 27109766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical evidence on polymer-based sirolimus and paclitaxel eluting stents.
    Iijima R; Mehilli J; Schömig A; Kastrati A
    Minerva Cardioangiol; 2006 Oct; 54(5):539-55. PubMed ID: 17019392
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Coronary arterial remodeling and out-stent plaque change after drug-eluting stent implantation--comparison between zotarolimus-eluting stents and paclitaxel-eluting stents.
    Muraoka Y; Sonoda S; Kashiyama K; Kamezaki F; Tsuda Y; Araki M; Tamura M; Takeuchi M; Abe H; Okazaki M; Otsuji Y
    Circ J; 2013; 77(2):363-71. PubMed ID: 23117679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of a novel slow-release paclitaxel-eluting stent with a bioabsorbable polymeric surface coating.
    Jabara R; Chronos N; Conway D; Molema W; Robinson K
    JACC Cardiovasc Interv; 2008 Feb; 1(1):81-7. PubMed ID: 19393150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of a paclitaxel coated balloon in combination with a bare metal stent on restenosis and endothelial function: comparison with a drug eluting stent and a bare metal stent.
    Clever YP; Cremers B; Speck U; Dietz U; Böhm M; Scheller B
    Catheter Cardiovasc Interv; 2014 Aug; 84(2):323-31. PubMed ID: 23996969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Electrosprayed Montelukast/poly (lactic-co-glycolic acid) particle based coating: A new therapeutic approach towards the prevention of in-stent restenosis.
    Zamani M; Prabhakaran MP; Varshosaz J; Mhaisalkar PS; Ramakrishna S
    Acta Biomater; 2016 Sep; 42():316-328. PubMed ID: 27397493
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 6-Month Follow-Up of a Novel Biodegradable Drug-Eluting Stent Composed of Poly-L-Lactic Acid and Amorphous Calcium Phosphate Nanoparticles in Porcine Coronary Artery.
    Xiao J; Feng G; Kang G; Lan Z; Liao T; Kislauskis E; Chen J; Xia J; Wang Z; Huo Z; Wang Q; Xi T; McCarthy S; Jiang X; Wu T; Laham R
    J Biomed Nanotechnol; 2015 Oct; 11(10):1819-25. PubMed ID: 26502644
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel biodegradable drug-eluting stent composed of poly-L-lactic acid and amorphous calcium phosphate nanoparticles demonstrates improved structural and functional performance for coronary artery disease.
    Lan Z; Lyu Y; Xiao J; Zheng X; He S; Feng G; Zhang Y; Wang S; Kislauskis E; Chen J; McCarthy S; Laham R; Jiang X; Wu T
    J Biomed Nanotechnol; 2014 Jul; 10(7):1194-204. PubMed ID: 24804540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug release kinetics from a drug-eluting stent with asymmetrical coat.
    Zhang H; Li X; Deng W; Wang X; Wang S; Ge J; Toft E
    Front Biosci (Landmark Ed); 2017 Jan; 22(3):407-415. PubMed ID: 27814621
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rationale and design for the PAINT randomized trial.
    Lemos PA; Moulin B; Perin MA; Oliveira LA; Arruda JA; Lima VC; Lima AA; Caramori PR; Medeiros CR; Barbosa MR; Brito FS; Ribeiro EE; Martinez EE;
    Arq Bras Cardiol; 2009 Dec; 93(6):547-53, 590-7. PubMed ID: 20379631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.